| Name | Title | Contact Details |
|---|
The MBX Difference: Relationship Based Partnerships Our bottom line in your bottom line. We don`t simply chase the low-hanging fruit. Put simply, our outsourced revenue cycle management will collect more dollars, improve your cash flow, support your physicians and delight your patients. MBX is a growing organization specializing in radiology billing. With MBX, from the start of our relationship to go live, you are in safe hands. Our experienced leadership team, who between them possess over seven decades of working with some of the nation’s leading radiology group practices, has implemented over 300 outsourced revenue cycle management systems. We process millions of procedures per year for practices from coast to coast, as diverse as three provider interventional radiologists in Oregon to a 100+ provider practice in North Carolina. MBX delivers consistent and exceptional revenue cycle management. We bill and collect every possible dollar by capitalizing on operational expertise that is second to none. Our exceptional rate of claims accepted the first time, along with our strong denials management process, ensures that claims are processed quickly and denials handled efficiently and effectively. Our end-to-end service extends from the point at which we receive the physician’s dictated report all the way through to the patient’s account at zero balance – we worry about the billing, you lower your operational overheads.
Santera Rehabilitation Inc is a Bristol, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Profil Institute for Clinical Research is a Chula Vista, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
First Databank is a major provider of drug and medical device databases that help inform healthcare professionals to make decisions.
Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.